<?xml version="1.0" encoding="UTF-8"?>
<p id="p0450">Dasabuvir 
 <bold>(32)</bold> (
 <xref rid="f0030" ref-type="fig">Fig. 6</xref> ) is a drug from the naphthalene class and phenyl-naphthalene subclass due to the bond between its naphthalene ring and a phenyl group. Dasabuvir is a first line drug used as combined therapy for chronic hepatitis C.
 <xref rid="b1035" ref-type="bibr">
  <sup>207</sup>
 </xref> Dasabuvir is a non-nucleoside inhibitor that binds to Nps5B (non-structural protein 5B â€“ RdRp) and induces conformational change that makes RdRp incapable of elongating the viral RNA.
 <xref rid="b1040" ref-type="bibr">
  <sup>208</sup>
 </xref> Repurposing of this drug can be useful as SARS-CoV-2 therapy due to its antiviral activity.
 <xref rid="b1045" ref-type="bibr">
  <sup>209</sup>
 </xref>
</p>
